The impact of describing clinical trial treatments as new or standard

C. E. P. Kerr, E. J. Robinson, R. J. Lilford, S. J. L. Edwards, David Alexander Braunholtz, A. J. Stevens

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Concern has been expressed over a possible widespread belief amongst patients in trials, that a new treatment is better than the standard, despite the lack of evidence of such superiority. A sample of the general public (N = 130) read a leaflet describing a hypothetical trial comparing two similar treatments for either arthritis or back-pain. Half read that both treatments were standard and generally available; half that one was new and available only within the trial. Participants rated any preference for one or the other treatment, gave written reasons, and indicated their willingness to enter the randomized trial. Fifteen participants subsequently talked through their answers. Most participants expressed no preference for either treatment when both were described as standard. When one was new more people with the arthritis (but not the back-pain) scenario expressed a preference (chi(2) = 5.44, P = 0.031). Importantly, this was not more likely to be for the new treatment. Rationally, those who preferred a freely available treatment were less likely to participate in the trial (chi(2) = 23.3, P < 0.001). The mere description of a trial treatment as new was insufficient to engender a preference for it over a standard treatment, although it may contribute to preference under certain additional circumstances. (C) 2003 Elsevier Science Ireland Ltd. All rights reserved.

Original languageEnglish
Pages (from-to)107-13
Number of pages7
JournalPatient Education and Counseling
Volume53
DOIs
Publication statusPublished - 2004

Keywords

  • new treatments
  • treatment preference
  • clinical trial participation
  • CANCER-PATIENTS
  • RANDOMIZATION
  • ATTITUDES
  • CONSENT

Cite this

Kerr, C. E. P., Robinson, E. J., Lilford, R. J., Edwards, S. J. L., Braunholtz, D. A., & Stevens, A. J. (2004). The impact of describing clinical trial treatments as new or standard. Patient Education and Counseling, 53, 107-13. https://doi.org/10.1016/S0738-3991(03)00124-1

The impact of describing clinical trial treatments as new or standard. / Kerr, C. E. P.; Robinson, E. J.; Lilford, R. J.; Edwards, S. J. L.; Braunholtz, David Alexander; Stevens, A. J.

In: Patient Education and Counseling, Vol. 53, 2004, p. 107-13.

Research output: Contribution to journalArticle

Kerr, CEP, Robinson, EJ, Lilford, RJ, Edwards, SJL, Braunholtz, DA & Stevens, AJ 2004, 'The impact of describing clinical trial treatments as new or standard', Patient Education and Counseling, vol. 53, pp. 107-13. https://doi.org/10.1016/S0738-3991(03)00124-1
Kerr, C. E. P. ; Robinson, E. J. ; Lilford, R. J. ; Edwards, S. J. L. ; Braunholtz, David Alexander ; Stevens, A. J. / The impact of describing clinical trial treatments as new or standard. In: Patient Education and Counseling. 2004 ; Vol. 53. pp. 107-13.
@article{45b4dd03332c439da1e3210d1a66bcfd,
title = "The impact of describing clinical trial treatments as new or standard",
abstract = "Concern has been expressed over a possible widespread belief amongst patients in trials, that a new treatment is better than the standard, despite the lack of evidence of such superiority. A sample of the general public (N = 130) read a leaflet describing a hypothetical trial comparing two similar treatments for either arthritis or back-pain. Half read that both treatments were standard and generally available; half that one was new and available only within the trial. Participants rated any preference for one or the other treatment, gave written reasons, and indicated their willingness to enter the randomized trial. Fifteen participants subsequently talked through their answers. Most participants expressed no preference for either treatment when both were described as standard. When one was new more people with the arthritis (but not the back-pain) scenario expressed a preference (chi(2) = 5.44, P = 0.031). Importantly, this was not more likely to be for the new treatment. Rationally, those who preferred a freely available treatment were less likely to participate in the trial (chi(2) = 23.3, P < 0.001). The mere description of a trial treatment as new was insufficient to engender a preference for it over a standard treatment, although it may contribute to preference under certain additional circumstances. (C) 2003 Elsevier Science Ireland Ltd. All rights reserved.",
keywords = "new treatments, treatment preference, clinical trial participation, CANCER-PATIENTS, RANDOMIZATION, ATTITUDES, CONSENT",
author = "Kerr, {C. E. P.} and Robinson, {E. J.} and Lilford, {R. J.} and Edwards, {S. J. L.} and Braunholtz, {David Alexander} and Stevens, {A. J.}",
year = "2004",
doi = "10.1016/S0738-3991(03)00124-1",
language = "English",
volume = "53",
pages = "107--13",
journal = "Patient Education and Counseling",
issn = "0738-3991",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - The impact of describing clinical trial treatments as new or standard

AU - Kerr, C. E. P.

AU - Robinson, E. J.

AU - Lilford, R. J.

AU - Edwards, S. J. L.

AU - Braunholtz, David Alexander

AU - Stevens, A. J.

PY - 2004

Y1 - 2004

N2 - Concern has been expressed over a possible widespread belief amongst patients in trials, that a new treatment is better than the standard, despite the lack of evidence of such superiority. A sample of the general public (N = 130) read a leaflet describing a hypothetical trial comparing two similar treatments for either arthritis or back-pain. Half read that both treatments were standard and generally available; half that one was new and available only within the trial. Participants rated any preference for one or the other treatment, gave written reasons, and indicated their willingness to enter the randomized trial. Fifteen participants subsequently talked through their answers. Most participants expressed no preference for either treatment when both were described as standard. When one was new more people with the arthritis (but not the back-pain) scenario expressed a preference (chi(2) = 5.44, P = 0.031). Importantly, this was not more likely to be for the new treatment. Rationally, those who preferred a freely available treatment were less likely to participate in the trial (chi(2) = 23.3, P < 0.001). The mere description of a trial treatment as new was insufficient to engender a preference for it over a standard treatment, although it may contribute to preference under certain additional circumstances. (C) 2003 Elsevier Science Ireland Ltd. All rights reserved.

AB - Concern has been expressed over a possible widespread belief amongst patients in trials, that a new treatment is better than the standard, despite the lack of evidence of such superiority. A sample of the general public (N = 130) read a leaflet describing a hypothetical trial comparing two similar treatments for either arthritis or back-pain. Half read that both treatments were standard and generally available; half that one was new and available only within the trial. Participants rated any preference for one or the other treatment, gave written reasons, and indicated their willingness to enter the randomized trial. Fifteen participants subsequently talked through their answers. Most participants expressed no preference for either treatment when both were described as standard. When one was new more people with the arthritis (but not the back-pain) scenario expressed a preference (chi(2) = 5.44, P = 0.031). Importantly, this was not more likely to be for the new treatment. Rationally, those who preferred a freely available treatment were less likely to participate in the trial (chi(2) = 23.3, P < 0.001). The mere description of a trial treatment as new was insufficient to engender a preference for it over a standard treatment, although it may contribute to preference under certain additional circumstances. (C) 2003 Elsevier Science Ireland Ltd. All rights reserved.

KW - new treatments

KW - treatment preference

KW - clinical trial participation

KW - CANCER-PATIENTS

KW - RANDOMIZATION

KW - ATTITUDES

KW - CONSENT

U2 - 10.1016/S0738-3991(03)00124-1

DO - 10.1016/S0738-3991(03)00124-1

M3 - Article

VL - 53

SP - 107

EP - 113

JO - Patient Education and Counseling

JF - Patient Education and Counseling

SN - 0738-3991

ER -